SMO and mesothelioma: Statistical analysis of SMO and GLI1 protein expression and clinicopathological data showed that the expression levels in patients with malignant mesothelioma were negatively correlated with age, history of exposure to asbestos chemicals, mesothelioma site, Ki67, and P53 expression (P < 0.05) and not significantly correlated with patient gender (P > 0.05).